Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody
Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody
复制标题
DOI：
10.1111/j.1365-2141.2006.06245.x
复制
发表时间：
2006-10-01
影响因子：
6.5
通讯作者：
Tremblay, Tony
中科院分区：
文献类型：
--
作者：
Bazin, Renee;Lemieux, Real;Tremblay, Tony
静脉注射免疫球蛋白(IVIgs)被用于治疗越来越多的自身免疫性疾病，但其确切作用机制尚不清楚。这项研究表明，与静脉注射免疫球蛋白相比，在静脉注射免疫球蛋白制剂中存在的人免疫球蛋白的交联会产生复合体，比静脉注射免疫球蛋白更有效地预防或逆转小鼠的血小板减少症。此外，只需将该单抗加入人血清中即可得到生物活性的复合体。这些结果表明，通过体外和体内形成含有免疫性血小板减少性紫癜患者自体免疫球蛋白的免疫复合体，可能开发出一种不含IVIg的替代品。
Intravenous immunoglobulins (IVIgs) are used to treat an increasing number of autoimmune diseases, but their exact mechanism of action remains unknown. This study showed that cross-linking of human IgG present in IVIg preparations using a mouse monoclonal anti-human IgG generated complexes that prevented or reversed thrombocytopenia in mice more efficiently than IVIg. Furthermore, biologically active complexes were obtained simply by adding the monoclonal antibody to human serum. These results suggest the possible development of an IVIg-free substitute through the ex vivo, and possibly in vivo, formation of immune complexes containing autologous IgG of immune thrombocytopenic purpura patients.